QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 限定条件 发表日期：2019     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial 期刊论文 JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2019, 卷号: 52, 期号: 1 作者:  Yuan, Jinyi;  Mo, Biwen;  Ma, Zhuang;  Lv, Yuan;  Cheng, Shih-Lung 收藏  |  浏览/下载：30/0  |  提交时间：2019/12/05 Clinical outcome  Community-acquired pneumonia  Levofloxacin  Nemonoxacin  Randomized controlled trial  Safety   Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial 期刊论文 JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2019, 卷号: 52, 期号: 1 作者:  Perng, Wann Cherng;  Chuang, Yin Ching;  Wu, Xiaoju;  Xiao, Yi;  Shen, Ce 收藏  |  浏览/下载：46/0  |  提交时间：2019/12/05 Clinical outcome  Community-acquired pneumonia  Levofloxacin  Nemonoxacin  Randomized controlled trial  Safety   Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial 期刊论文 JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2019, 卷号: 52, 期号: 1 作者:  Yuan, Jinyi;  Mo, Biwen;  Ma, Zhuang;  Lv, Yuan;  Cheng, Shih-Lung 收藏  |  浏览/下载：47/0  |  提交时间：2019/12/05 Clinical outcome  Community-acquired pneumonia  Levofloxacin  Nemonoxacin  Randomized controlled trial  Safety   Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial 期刊论文 2019, 卷号: 52, 期号: 1, 页码: 35-44 作者:  Yuan, Jinyi;  Mo, Biwen;  Ma, Zhuang;  Lv, Yuan;  Cheng, Shih-Lung 收藏  |  浏览/下载：29/0  |  提交时间：2020/01/03 Clinical outcome  Community-acquired pneumonia  Levofloxacin  Nemonoxacin  Randomized controlled trial  Safety